Industry Reports

Bringing a pharmaceutical product to market is hard work. Pre-market regulatory requirements in the United States and the European Union are well established and generally well understood by experienced development teams. And it still years and millions of dollars...

Asia-Pacific’s biotechnology landscape is not just growing it is transforming. In 2026, the region stands at a unique crossroads where scientific ambition meets real-world demands. This year will test the industry’s resilience, shape global health priorities, and redefine how...

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Cardiovascular diseases, gastrointestinal conditions and cancer are top medical conditions expected to drive medical plan costs   Aon plc, a leading global professional services firm, today released the India findings from its 2026 Global Medical Trend Rates Report. The report...

It should be highlighted that during the next ten years, it is expected that the global biopharmaceutical CMO and CRO markets would expand significantly. The market is anticipated to grow at a compound annual growth rate (CAGR) of over...